PRESS RELEASE published on 04/25/2024 at 07:30, 2 years 5 months ago Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance Formycon reports audited annual results for the financial year 2023, exceeding guidance with an 83% increase in group revenue. Positive EBITDA and outlook for 2024 announced 2024 Outlook Financial Year 2023 Group Revenue Annual Results Formycon
BRIEF published on 04/22/2024 at 07:35, 2 years 5 months ago Formycon Announces Financial Results Conference Call and Upcoming Investor Conferences Financial Results Conference Call 2024 Outlook Investor Conferences Formycon AG
BRIEF published on 04/22/2024 at 07:35, 2 years 5 months ago Formycon annonce une conférence téléphonique sur les résultats financiers et les prochaines conférences pour les investisseurs Résultats Financiers Perspectives 2024 Formycon AG Conférence Téléphonique Conférences Investisseurs
PRESS RELEASE published on 04/22/2024 at 07:30, 2 years 5 months ago Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024 Formycon AG invites to conference call for 2023 financial year results and announces participation in upcoming international investor conferences Conference Call Investor Conferences Formycon AG Biosimilars Financial Year Results
BRIEF published on 04/12/2024 at 22:20, 2 years 5 months ago Formycon Surpasses Financial Expectations in 2023, Lays Foundation for Future Growth Financial Results EBITDA Revenue Growth Biosimilars Formycon
BRIEF published on 04/12/2024 at 22:20, 2 years 5 months ago Formycon dépasse les attentes financières en 2023 et jette les bases d'une croissance future Résultats Financiers Hausse Des Revenus BAIIA Formycon Biosimilaires
PRESS RELEASE published on 04/12/2024 at 22:15, 2 years 5 months ago Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast Formycon reports strong preliminary results for the financial year 2023, with a Group revenue increase of 83% to €77.7 million, positive Group EBITDA achieved, and a new key financial performance indicator introduced Financial Results Formycon AG Biosimilar Pipeline Group Revenue Adjusted Group EBITDA
BRIEF published on 04/12/2024 at 19:32, 2 years 5 months ago Formycon AG Announces Preliminary Financial Results for 2023 and Forecasts for 2024 Financial Results Biotechnology 2024 Guidance Formycon AG 2023 Forecast
BRIEF published on 04/12/2024 at 19:32, 2 years 5 months ago Formycon AG annonce ses résultats financiers préliminaires pour 2023 et ses prévisions pour 2024 Résultats Financiers Biotechnologie Formycon AG Prévisions 2023 Orientation 2024
PRESS RELEASE published on 04/12/2024 at 19:27, 2 years 5 months ago EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year Formycon AG publishes preliminary figures for 2023 financial year and guidance for 2024. EBITDA expected around EUR 1.5 million for 2023 and revenues of EUR 55-65 million for 2024 EBITDA 2023 Financial Year Formycon AG Preliminary Figures 2024 Financial Year
Published on 10/05/2026 at 22:30, 2 hours 7 minutes ago EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Published on 10/05/2026 at 14:45, 9 hours 52 minutes ago NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 10 hours 7 minutes ago Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 10 hours 7 minutes ago Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 10 hours 37 minutes ago Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Published on 10/05/2026 at 22:25, 2 hours 12 minutes ago LumApps Named a Leader in 2026 Gartner® Magic Quadrant™ for Intranet Packaged Solutions
Published on 10/05/2026 at 22:05, 2 hours 32 minutes ago AMPERA SUBMITS COMPREHENSIVE ENGAGEMENT PLAN TO THE U.S. NUCLEAR REGULATORY COMMISSION
Published on 10/05/2026 at 21:10, 3 hours 27 minutes ago Shelly Group Board of Directors considers EUR 70.00 offer price fair and supports Schneider Electric’s voluntary public tender offer
Published on 10/05/2026 at 21:05, 3 hours 32 minutes ago EQS-Adhoc: Shelly Group SE: Board of Directors with positive opinion on the registered voluntary public tender offer by Schneider Electric SE
Published on 10/05/2026 at 20:15, 4 hours 22 minutes ago EQS-Adhoc: United Internet AG participates in capital increase against contributions in kind at 1&1 AG
Published on 10/05/2026 at 22:12, 2 hours 25 minutes ago AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 22:12, 2 hours 25 minutes ago AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Published on 10/05/2026 at 18:13, 6 hours 24 minutes ago Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 6 hours 24 minutes ago Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 6 hours 37 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026